Effectiveness of prolonged-release melatonin in improving insomnia and depression in patients with epilepsy

Key Points

• Improved insomnia and depression were notable among participants using prolonged-release melatonin, supporting its therapeutic potential.
• Average scores for insomnia decreased by 35% after melatonin treatment, with significant effects observed after eight weeks of intervention.
• Observational analysis across multiple epilepsy centers assessed melatonin's impact on mental health over a substantial period.
• Findings support the role of melatonin in managing psychiatric comorbidities in epilepsy, but need further investigation for broader implications.